How Long ANMAT Takes: Research Product Queries

For informal technical queries, ANMAT establishes no legal response deadline. The range reported by Argentine research institutions is thirty to ninety business days, and a significant share of informal queries receive no formal written reply at all. For formal clinical trial authorizations, Argentine regulations specify a sixty-business-day review period from the submission of a complete dossier; in practice, the full cycle runs four to eight months, because observation letters interrupt and restart that clock. The type of interaction determines everything about the expected timeline.

What ANMAT Means by a Query

Two very different types of communication arrive at ANMAT, and the distinction matters before estimating any timeline.

The first is an informal technical query: a researcher or institution writes to ask about a compound, a regulatory classification or a procedural pathway. These queries carry no statutory response deadline. ANMAT replies when operational capacity allows, and silence running several months is routine. Sending a query by email does not create a deadline obligation for the agency.

The second category covers formal procedures: clinical trial protocol authorizations, importation approvals for research materials, expanded access or compassionate use requests. These carry regulatory timelines. If ANMAT fails to respond within the statutory window, administrative remedies become available to the applicant.

When a response is needed by a known date, a formal procedure is the only path that carries an enforceable deadline.

Regulatory Timelines by Procedure Type

Clinical Trial Authorization

Argentine regulations require ANMAT to render a decision on a clinical trial protocol within sixty business days from the date of a complete submission. The practical cycle runs four to eight months for most protocols, because "complete submission" is rarely achieved on the first attempt. Each observation letter ANMAT issues suspends the clock; the clock restarts when the applicant responds. A protocol that generates two rounds of observations can translate the statutory sixty days into substantially more calendar time.

The submission channel for clinical trials in Argentina is SiGMAIC — the Sistema de Gestión y Monitoreo de Investigación Clínica — ANMAT's formal platform for that category of dossier. Attempting to manage a clinical trial authorization through informal email correspondence will not produce a binding decision.

Expanded Access and Compassionate Use

Expanded access, also called compassionate use, applies to individual patients with no available therapeutic alternative when the compound is under active investigation. With a complete individual dossier and documented urgency, the single-patient procedure can resolve in approximately twenty business days. Multi-patient expanded access programmes resemble a clinical trial in complexity and carry timelines closer to the formal trial path.

Importation for Research Purposes

Unregistered compounds may require a prior ANMAT authorization before importation, depending on how the material is classified and the declared use. When an authorized clinical trial protocol is already in place and the material is covered by it, the administrative processing can resolve in two to four weeks. Without a prior approved protocol, the same importation can take several months.

Why Many Research Materials Do Not Go Through ANMAT

ANMAT's registration process is built for medicines and therapeutic products: substances administered to patients in the context of diagnosis, treatment or prevention of disease. Law 16,463 and its regulations define that universe. Not every compound enters through that door.

Materials classified as RUO (Research Use Only) operate in a different category. They are laboratory inputs: used in in vitro studies, basic research and institutional protocols where the laboratory employs the compound as a reagent or starting material, not as a medicine administered to a patient. The pharmaceutical registration process ANMAT administers does not apply to that type of material.

That is not the same as no regulation. Any imported compound is subject to customs rules and export controls at origin. The receiving institution manages its own internal biosafety and handling protocols. But the medicine-registration pathway is a different process serving a different category of product.

The research peptides PeptoClinic Research Supply quotes for laboratory destinations in Argentina fall in this category: they are supplied as reference materials with complete technical documentation, outside the medicine-registration process.

What Documentation Accompanies a Research Material

When a laboratory receives a compound classified as RUO, what it verifies is not an ANMAT registration number. It verifies the Certificate of Analysis (CoA): the document that certifies the compound's identity, the analysed purity and the independent laboratory that performed the analysis.

PeptoClinic Research Supply's materials ship with reports from Janoshik Analytical, an independent analytical laboratory whose results are verifiable on the laboratory's own platform. Current published batches show a minimum purity of 99.669 % by HPLC.

Retatrutide available for Argentina, as one example, is covered by Janoshik task 136921, analysed on April 13, 2026, with a verified purity of 99.893 %. The complete documentation for active batches — compound, task number, purity found and the laboratory that signed the report — is collected on the PeptoClinic quality page.

For Laboratory Research Only

The materials described in this article are classified strictly as Research Use Only (RUO), intended for in vitro and laboratory research.

None of these compounds is approved or authorized by ANMAT, the FDA or any equivalent authority for human or veterinary use. PeptoClinic Research Supply is not a pharmacy, a clinic or a medicine supplier. No prescriptions are written, accepted or required. Requests for administration protocols or dosing guidance for persons are declined.

When ANMAT Interaction Is Necessary

If the objective is to incorporate a compound into a formal clinical trial involving human subjects in Argentina, the regulatory process begins well before material acquisition.

A clinical trial protocol is submitted through SiGMAIC. Required documentation includes the full protocol, the investigator's brochure, the informed consent template and the approval of the institutional ethics committee. Only with that authorization in place does it make sense to discuss material supply for the protocol.

The clinical trials section of ANMAT maintains current forms and requirements for initiating that type of application.

Reading ANMAT's Silence on an Informal Query

An email query sent to ANMAT may go unanswered for weeks or months. That silence does not mean the compound is prohibited or that the activity is irregular. ANMAT does not have the operational capacity to formally respond to all informal queries about research compounds, and administrative silence is not a prohibition.

The PeptoClinic catalogue lists materials available for laboratory research, with the analytical documentation for each compound.